Navigation Links
Ceralas D

ProductsCeralas D
Company biolitec, Inc.
Item Ceralas D
Features 
  • Provides unsurpassed absorption in water and hemoglobin
  • Allows controlled tissue ablation and provides a bloodless field for most surgical procedures
  • Cuts and coagulates optically with negligible collateral tissue damage, charring, and recession
  • Many procedures using the 980nm lasers are pain-free, minimizing or even eliminating the need for anesthesia
  • Compact and portable at 15 pounds and require no special cooling or maintenance
    • Description biolitecs Ceralas D 980 nm diode laser provides controlled tissue ablation and a clean, bloodless field for most surgical procedures. Unlike other medical lasers, the Ceralas D cuts optically without collateral tissue damage or charring. The Ceralas D laser coagulates blood instantly and seals small blood vessels thereby minimizing inflammation and the usual discomfort that is associated with most surgeries. As a surgical instrument, the Ceralas D laser makes extremely accurate, bloodless incisions. It provides superb hemostasis, allowing doctors a clear view of the operating field and enhancing patient recovery. Post-operative comfort is another advantage over conventional surgical modalities and even other lasers. The Ceralas D reduces the need for anesthetic, minimizes post-operative discomfort, and enhances patient recovery. Also, the laser is often more efficient than traditional surgical procedures, resulting in reduced operating time and increased patient turnover rates. Weighing only 15 pounds, the Ceralas D is user-friendly, compact, and portable making it ideal for inter-office, hospital, surgery center, or nursing home use. Also, biolitecs Ceralas D laser is essentially maintenance-free because it does not require water cooling or parts that need special maintenance.
    Info biolitec, Inc.
    Customer Service: (800) 934-2377
    Web site: http://www.biolitec-us.com/default.asp

    Related medicine products :

    1. Ceralas D15/810 10-Watt 810 nm Diode Laser
    2. Ceralas G5 Diode-Pumped Nd:YAG Laser
    3. Ceralas D 980nm Diode Laser
    TAG: Ceralas
    ...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
    ...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
    ...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
    ...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
    Medicine Products:
    (Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
    (Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
    (Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
    (Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
    Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
    ...ontessori schools have an advantage over other kid.... However, an early education researcher finds the...s study, thirty 5-year old kids and twenty nine 12...ner-city Montessori school in Milwaukee, Wis. were...
    ...alth (NIH) announced that they have finished the p...ics in Parkinson's disease//. The study is far fro...g point for future detailed studies. The study was...stitute of Aging (NIA) and National Institute of N...
    ...c Policy Center (GPPC) says that fertility clinics...ds' gender by using// a method called preimplantat...tended to allow embryos to be screened for deadly ... a 3-day-old embryo and screens for presence of ch...
    ...e that could detect hidden fractures once a person...kus and colleagues at Purdue University in Indiana...ound waves created by tiny cracks in damaged bones...on of Daily Mail. They then sound an alarm, warni...
    Other Medicine News:Health News:Montessori Schools kids do better in Reading and Math 2Health News:Parkinson's Disease And Genetics 2Health News:Fertility Clinics Allowing Parents To Select Gender 2
    (Date:9/3/2008)... analysis showed that Multaq(R) (dronedarone) decr...rial fibrillation or atrial flutter already ...y, BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCa...ata from the ATHENA study were presented today at,...Society of Cardiology,congress 2008, in Munich, Ge...
    (Date:9/3/2008)...mpany Focuses Operations, Updates Zingo Launch Pro...on Strategy Conference Call Today...t. 3 /- Anesiva,Inc. (Nasd...restructure,operations to focus on commercial and ...ransition to a specialty pharmaceutical pain manag...
    (Date:9/3/2008)...B-509 to be Evaluated in Repeat-Dosing Study in Su...swire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nas...Phase,2 clinical trial (SB-509-801) to evaluate it...e, degenerative motor-neuron disease for which the...ngamo,s drug, SB-509, is an injectable formulation...
    (Date:9/2/2008)...W YORK, Sept. 3 /- Forest L...lmirall, S.A. today announced results from,two glo...el long-acting,inhaled anticholinergic for the tre...ary disease (COPD). In both the ACCLAIM/COPD I&II,...Safety In Moderate to,Severe COPD Patients) studie...
    Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Indivumed Appoints Annette Kassen as Vice President Clinical Research 4500 1Indivumed Appoints Annette Kassen as Vice President Clinical Research 4500 2Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 1Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 2Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 3Module map links embryonic stem cells and cancer stem cells 16381 1Module map links embryonic stem cells and cancer stem cells 16381 2 26 23163 3B7 5m to transform patient care 16379 1 26 23163 3B7 5m to transform patient care 16379 2 26 23163 3B7 5m to transform patient care 16379 3
    ...clinical data for potential combination,therapies ...after,ITMN-191 exposure, BARCELONA, Spain, April 1...announced today the presentation of findings from,...ease inhibitor,ITMN-191, alone or in combination w... the European Association for the Study of the,Liv...
    ...SS WIRE)--Apr 11, 2007 - New data,supporting the c...,the most advanced investigational oral protease i...HCV) infection, will be presented,at the 42nd Annu...dy of the Liver (EASL) in Barcelona this week. In ...een accepted for presentation,at the EASL conferen...
    Other Medicine Technology:InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6